Benedetta Mazzanti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Benedetta Mazzanti has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Vespasiano
Istituto Superiore di Sanita
1 shared publication - Letizia Lombardini
Centro Nazionale Trapianti, Istituto Superiore di Sanità, 00161 Roma, Italy
1 shared publication - Maria Chiara de Stefano
Italian National Transplant Centre, Italian National Institute of Health, Rome, Italy
1 shared publication - Massimo Cardillo
Trapianti Lombardia - NITp, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 5 April 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (4) , 480
The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy
Faecal microbiota transplantation (FMT) is regarded as an efficacious treatment for recurrent C. difficile infection. Unfortunately, widespread patient access is hindered by regulatory hurdles, which are the primary barriers to incorporating FMT into clinical practice. At the European and International level, there is no uniform perspective on FMT classification, and a coordinated effort is desirable to solve this regulatory puzzle. In this communication, we report the regulatory principles and the implementation approach for FMT application in Italy. Our experience suggests that the EU Tissue and Cell Directives are suited to ensure safe and efficient FMT for C. difficile management, especially through extensive high-quality donor selection and full traceability maintenance.
- 5 April 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (4) , 480
Open AccessThe Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy
Faecal microbiota transplantation (FMT) is regarded as an efficacious treatment for recurrent C. difficile infection. Unfortunately, widespread patient access is hindered by regulatory hurdles, which are the primary barriers to incorporating FMT into clinical practice. At the European and International level, there is no uniform perspective on FMT classification, and a coordinated effort is desirable to solve this regulatory puzzle. In this communication, we report the regulatory principles and the implementation approach for FMT application in Italy. Our experience suggests that the EU Tissue and Cell Directives are suited to ensure safe and efficient FMT for C. difficile management, especially through extensive high-quality donor selection and full traceability maintenance.